Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO1991014790 - INHIBITEURS D'ACTIVITES RELATIVES A L'ACTIVATION DE LA TRANSCRIPTION CHEZ LES VIRUS DU PAPILLOME

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

Claims
1. A method for identifying an inhibitor of the transcription activation activity of a
papillomavirus "E6 peptide, comprising the steps, of:
providing a papillomavirus E6 peptide having transcriptional activation activity bonded with a
heterologous nucleic acid binding domain having specific nucleic acid binding activity,
providing nucleic acid encoding a detectable protein in transcription relationship with nucleic acid to which said heterologous nucleic* acid binding domain binds,
providing a potential inhibitor,
contacting said hybrid peptide with said
nucleic acid in the presence of said potential inhibitor to cause transcription of said nucleic acid to produce a predetermined level of said detectable protein when said potential inhibitor is inactive to inhibit said
transcription activation activity, and to produce a lower level of said detectable protein than said
predetermined level when said potential inhibitor is active to inhibit said transcription activation activity.

2. The method of claim 1, wherein said nucleic acid is provided within a cell, said detectable protein is lethal to said cell, said potential inhibitor is encoded by a second nucleic acid within said cell, and only a cell comprising said inhibitor survives after said contacting step.

3. A method to inhibit the transcription activation activity of papillomavirus E6 in a patient, comprising the steps of:
providing a therapeutically effective amount of an inhibitor of the transcription activation activity of a papillomavirus E6 peptide which reduces the
transcription activation activity of the E6 peptide in vitro; and
administering said inhibitor to said patient.

4. A hybrid peptide comprising a
papillomavirus E6 peptide having transcription
activation activity covalently bonded with a
heterologous nucleic acid binding domain having specific nucleic acid binding activity.

5. The hybrid peptide of claim 4 wherein said nucleic acid binding domain is chosen from a domain which binds to a promoter or enhancer region of
eucaryotic DNA.

6. The hybrid peptide of claim 4 wherein said E6 peptide is that peptide encoded by BPV or HPV.

7. Nucleic acid encoding a papillomavirus E6 peptide having transcription activation activity fused to a heterologous nucleic acid binding domain having specific nucleic acid binding activity.

8. The nucleic acid of claim 7 wherein said nucleic acid binding domain is chosen from a domain which binds to a promoter or enhancer region of
eucaryotic DNA.

9. The nucleic acid of claim 7 wherein said E6 peptide is that peptide encoded by BPV or HPV.

10. An inhibitor of the transcription
activation activity of a papilloma virus E6 peptide, said inhibitor reducing said transcriptional activation activity of said E6 peptide in vitro.

11. The inhibitor of claim 10 comprising an inhibitory fragment of a papillomavirus E6 peptide lacking transcriptional activation activity.

12. The inhibitor of claim 11 wherein said peptide has a chemical moiety which covalently bonds with eucaryotic DNA and prevents activation of said DNA by a papillomavirus E6 peptide.

13. The inhibitor of claim 10 wherein said inhibitor interferes with the interaction of said E6 with nucleic acid.